OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Weijie Ma, Ruobing Xue, Zheng Zhu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 64
Weijie Ma, Ruobing Xue, Zheng Zhu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 64
Showing 1-25 of 64 citing articles:
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Letong Cai, Yuchen Li, Jiaxiong Tan, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 125
Letong Cai, Yuchen Li, Jiaxiong Tan, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 125
Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data
Deniz Can Güven, Enes Erul, Yunus Kaygusuz, et al.
Supportive Care in Cancer (2023) Vol. 31, Iss. 11
Closed Access | Times Cited: 98
Deniz Can Güven, Enes Erul, Yunus Kaygusuz, et al.
Supportive Care in Cancer (2023) Vol. 31, Iss. 11
Closed Access | Times Cited: 98
Pulmonary toxicity of immune checkpoint immunotherapy
Mohammad I. Ghanbar, Karthik Suresh
Journal of Clinical Investigation (2024) Vol. 134, Iss. 2
Open Access | Times Cited: 21
Mohammad I. Ghanbar, Karthik Suresh
Journal of Clinical Investigation (2024) Vol. 134, Iss. 2
Open Access | Times Cited: 21
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside
Yue Yin, Weibo Feng, Jie Chen, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 19
Yue Yin, Weibo Feng, Jie Chen, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 19
Regulation of tumor immunity and immunotherapy by the tumor collagen extracellular matrix
Dallas B. Flies, Solomon Langermann, Christina Jensen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 31
Dallas B. Flies, Solomon Langermann, Christina Jensen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 31
Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 27
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 27
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors
Yuze Wu, Ming Yi, Mengke Niu, et al.
Cancer Communications (2024) Vol. 44, Iss. 7, pp. 739-760
Open Access | Times Cited: 8
Yuze Wu, Ming Yi, Mengke Niu, et al.
Cancer Communications (2024) Vol. 44, Iss. 7, pp. 739-760
Open Access | Times Cited: 8
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications
Hao Peng, Zheng Chao, Zefeng Wang, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Hao Peng, Zheng Chao, Zefeng Wang, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial
Gabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
Nature Cancer (2025)
Open Access | Times Cited: 1
Gabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
Nature Cancer (2025)
Open Access | Times Cited: 1
NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice
Junlei Hou, Shuanglong Xie, Jianbao Gao, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Junlei Hou, Shuanglong Xie, Jianbao Gao, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Lymphocyte-activation gene 3 (LAG-3) as a promising immune checkpoint in cancer immunotherapy: From biology to the clinic
Yaser E. Alqurashi
Pathology - Research and Practice (2024) Vol. 254, pp. 155124-155124
Closed Access | Times Cited: 7
Yaser E. Alqurashi
Pathology - Research and Practice (2024) Vol. 254, pp. 155124-155124
Closed Access | Times Cited: 7
Unveiling Anoikis‐related genes: A breakthrough in the prognosis of bladder cancer
Jiang Shen, Xiping Yang, Yang Lin, et al.
The Journal of Gene Medicine (2024) Vol. 26, Iss. 1
Closed Access | Times Cited: 7
Jiang Shen, Xiping Yang, Yang Lin, et al.
The Journal of Gene Medicine (2024) Vol. 26, Iss. 1
Closed Access | Times Cited: 7
Overexpression of ESYT3 improves radioimmune responses through activating cGAS-STING pathway in lung adenocarcinoma
Zan Luo, Ying Li, Bin Xu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Zan Luo, Ying Li, Bin Xu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Integrating immunopeptidome analysis for the design and development of cancer vaccines
Sara Feola, Jacopo Chiaro, Vincenzo Cerullo
Seminars in Immunology (2023) Vol. 67, pp. 101750-101750
Open Access | Times Cited: 13
Sara Feola, Jacopo Chiaro, Vincenzo Cerullo
Seminars in Immunology (2023) Vol. 67, pp. 101750-101750
Open Access | Times Cited: 13
The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma
Shan Hua, Wenhao Wang, Zuochao Yao, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 2
Open Access | Times Cited: 5
Shan Hua, Wenhao Wang, Zuochao Yao, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 2
Open Access | Times Cited: 5
Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma
Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, et al.
The Annals of Thoracic Surgery (2024) Vol. 118, Iss. 1, pp. 130-140
Closed Access | Times Cited: 5
Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, et al.
The Annals of Thoracic Surgery (2024) Vol. 118, Iss. 1, pp. 130-140
Closed Access | Times Cited: 5
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Carly D. Miller, John R. Lozada, Nicholas A. Zorko, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 5, pp. 1369-1379
Open Access | Times Cited: 5
Carly D. Miller, John R. Lozada, Nicholas A. Zorko, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 5, pp. 1369-1379
Open Access | Times Cited: 5
SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer
Jin Li, Yuxian Bai, Zhendong Chen, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 11
Open Access | Times Cited: 5
Jin Li, Yuxian Bai, Zhendong Chen, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 11
Open Access | Times Cited: 5
Comparative Study of the Immune Microenvironment in Heterotopic Tumor Models
Melanie Kienzl, Kathrin Maitz, Arailym Sarsembayeva, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 295-295
Open Access | Times Cited: 4
Melanie Kienzl, Kathrin Maitz, Arailym Sarsembayeva, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 295-295
Open Access | Times Cited: 4
Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors
Csaba Kerepesi, Hassan Abushukair, Biagio Ricciuti, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 4
Csaba Kerepesi, Hassan Abushukair, Biagio Ricciuti, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 4
TMBocelot: an omnibus statistical control model optimizing the TMB thresholds with systematic measurement errors
Xin Lai, Shaoliang Wang, Xuanping Zhang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Xin Lai, Shaoliang Wang, Xuanping Zhang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Metronomic vinorelbine combined with durvalumab plus tremelimumab dual immunotherapy in patients with metastatic prostate cancer
Elodie Coquan, Alice Hervieu, Claire Cropet, et al.
Research Square (Research Square) (2025)
Closed Access
Elodie Coquan, Alice Hervieu, Claire Cropet, et al.
Research Square (Research Square) (2025)
Closed Access
Dendritic cells-targeted delivery of mRNA vaccines and dual siRNAs via microneedles effectively inhibits tumor growth
Yifei Pei, Zhen Chen, Xiaoyun Wang, et al.
Journal of Drug Delivery Science and Technology (2025), pp. 106768-106768
Closed Access
Yifei Pei, Zhen Chen, Xiaoyun Wang, et al.
Journal of Drug Delivery Science and Technology (2025), pp. 106768-106768
Closed Access
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis
Yuze Wu, Yuheng Yan, Yarong Guo, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access
Yuze Wu, Yuheng Yan, Yarong Guo, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access
